通貨 / ALLO
ALLO: Allogene Therapeutics Inc
1.13
USD
0.05
(4.24%)
ALLOの今日の為替レートは、-4.24%変化しました。日中、通貨は1あたり1.11の安値と1.20の高値で取引されました。
Allogene Therapeutics Incダイナミクスに従います。リアルタイムの相場は、市場の変化に迅速に対応するのに役立ちます。 異なる時間枠に切り替えることで、為替レートの傾向とダイナミクスを分、時間、日、週、月単位で監視できます。この情報を使用して、市場の変化を予測し、十分な情報に基づいて取引を決定してください。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ALLO News
- Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
- Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
- Allogene Q2 Cash Tops $300 Million
- Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
- Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
- Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment
- This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics (NASDAQ:ALLO), AvalonBay Communities (NYSE:AVB)
- Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics (NASDAQ:ALLO)
- Adicet Bio stock rating initiated at Buy by H.C. Wainwright
- Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
- Allogene Therapeutics at Jefferies Conference: Delays and Optimism
- Citi maintains buy rating on Allogene stock following ASCO data
- H.C. Wainwright maintains buy rating on Allogene stock after ASCO update
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- Citizens JMP highlights key ASCO presentations
- Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
- Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner
- Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene shares update on CAR T-cell therapies at ASCO meeting
- Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
- Abrdn Life Sciences Investors Q4 2024 Commentary (NYSE:HQL)
1日のレンジ
1.11
1.20
1年のレンジ
0.86
3.78
- 以前の終値
- 1.18
- 始値
- 1.18
- 買値
- 1.13
- 買値
- 1.43
- 安値
- 1.11
- 高値
- 1.20
- 出来高
- 1.878 K
- 1日の変化
- -4.24%
- 1ヶ月の変化
- -5.83%
- 6ヶ月の変化
- -39.25%
- 1年の変化
- -56.37%
30 8月, 土曜日